Decheng Capital Management Iii (Cayman), LLC I Mab Call Options Transaction History
Decheng Capital Management Iii (Cayman), LLC
- $181 Million
- Q3 2023
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding IMAB
# of Institutions
34Shares Held
16.5MCall Options Held
0Put Options Held
14.5K-
Hhlr Advisors, Ltd. Grand Cayman, E95.98MShares$5.86 Million0.19% of portfolio
-
Morgan Stanley New York, NY3.54MShares$3.47 Million0.0% of portfolio
-
Sg Americas Securities, LLC476KShares$466,3440.0% of portfolio
-
David A. Siegel Two Sigma Advisers, LP | New York, Ny431KShares$422,1840.0% of portfolio
-
Two Sigma Investments, LP New York, NY330KShares$323,6010.0% of portfolio
About I-Mab
- Ticker IMAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 83,098,800
- Market Cap $81.4M
- Description
- I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...